What are the medications for hyperbilirubinemia (elevated bilirubin levels) in adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The primary treatment for hyperbilirubinemia in adults involves addressing the underlying cause, with medications such as ursodeoxycholic acid (UDCA) for cholestatic hyperbilirubinemia, phenobarbital for severe hemolysis, and antiviral medications for hepatitis, while discontinuing offending agents in drug-induced cases.

Treatment Approach

The treatment of hyperbilirubinemia in adults is highly dependent on the underlying etiology, which can range from unconjugated hyperbilirubinemia (e.g., Gilbert's syndrome) to conjugated hyperbilirubinemia due to biliary obstruction or hepatocellular disease 1.

  • For unconjugated hyperbilirubinemia, such as in Gilbert's syndrome, typically no specific medication is required, as it is often a benign condition that does not necessitate treatment beyond reassurance 1.
  • In cases of drug-induced or hepatocellular hyperbilirubinemia, the first step is to discontinue the offending agent, which can lead to resolution of the hyperbilirubinemia 1.
  • For severe hyperbilirubinemia due to hemolysis, phenobarbital at doses of 60-180 mg/day in divided doses can be utilized to enhance bilirubin conjugation and excretion, although this is less common in adults compared to neonates 1.
  • Cholestatic hyperbilirubinemia, which can result from primary biliary cholangitis, primary sclerosing cholangitis, or medication-induced liver injury, may be treated with ursodeoxycholic acid (UDCA) at doses of 13-15 mg/kg/day to improve bile flow 1.
  • In primary biliary cholangitis, UDCA at doses of 13-15 mg/kg/day is considered the standard treatment, aiming to slow the progression of the disease and improve symptoms 1.
  • For hyperbilirubinemia associated with hepatitis, the choice of antiviral medication depends on the viral cause, highlighting the importance of accurate diagnosis in guiding treatment 1.

Monitoring and Specialist Consultation

It is essential to monitor liver function tests during treatment to assess the response to therapy and adjust the treatment plan as necessary. Severe cases of hyperbilirubinemia or those with complex underlying conditions may require consultation with a hepatology specialist for optimal management 1. Given the most recent and highest quality evidence available, the treatment should always prioritize addressing the underlying cause of hyperbilirubinemia, as hyperbilirubinemia itself is typically a symptom rather than a disease entity, and management strategies should be tailored accordingly 1.

From the FDA Drug Label

PRINCIPAL DISPLAY PANEL NDC 0641-0477-21 Rx only Phenobarbital Sodium Injection, USP 130 mg/mL For IM or slow IV use Do not use if discolored or precipitated. 1 mL Vial NDC 0641-0477-25 Rx only Phenobarbital Sodium Injection, USP 130 mg/mL For IM or slow IV use Do not use if discolored or precipitated. 25 x 1 mL Vials

The FDA drug label does not answer the question.

From the Research

Medications for Hyperbilirubinemia in Adults

  • Rifampicin has been shown to be effective in treating severe hyperbilirubinemia, particularly in patients with persistent hyperbilirubinemia 2.
  • Phenobarbital has been found to improve hepatic clearance of ursodeoxycholic acid and reduce serum bilirubin levels in patients with Gilbert's syndrome 3.
  • Ursodeoxycholic acid may be used to treat certain types of hyperbilirubinemia, such as those associated with impaired hepatic transport of bile acids 3.
  • Antiviral medications may cause hyperbilirubinemia as a side effect, and modification of drug choice or dose may be required in cases of liver injury or hemolysis 4.
  • Ceftriaxone, an antibiotic, has been associated with reversible biliary sludge, pseudolithiasis, and cholestasis, and may cause marked direct hyperbilirubinemia in some patients, particularly those with sickle cell disease 5.

Treatment Approaches

  • The choice of medication for hyperbilirubinemia depends on the underlying cause of the condition and the presence of any underlying liver disease or other medical conditions 2, 3, 4, 5.
  • In some cases, elimination of the offending agent, such as a medication that is causing hyperbilirubinemia, may be necessary to improve the condition 5.
  • A careful history and physical examination, followed by directed imaging of the biliary tree and liver, are important steps in evaluating patients with jaundice and hyperbilirubinemia 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Hyperbilirubinemia in the setting of antiviral therapy.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2005

Research

Diagnosis and evaluation of hyperbilirubinemia.

Current opinion in gastroenterology, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.